Key Takeaways
- • Reed Jobs, son of Apple co-founder Steve Jobs, operates Yosemite, a $1bn+ oncology-focused venture capital fund motivated by his father's death from pancreatic cancer in 2011, with the stated mission to transform cancer into a non-lethal, treatable disease.
- • Yosemite has deployed capital across approximately 20 healthcare startups including Tune Therapeutics, Azalea Therapeutics, Chai Discovery, and Sage Care, with investment focus on gene therapy, cancer vaccines, radiopharmaceuticals, and artificial intelligence applications.
- • Reed Jobs is actively scouting UK investment opportunities and has already backed undisclosed UK companies; Yosemite receives institutional backing from LifeArc (a UK Medical Research Council spinoff focused on rare diseases) and maintains philanthropic grant partnerships with Oxford and Cambridge universities.
- • Yosemite operates a dual-structure model combining a for-profit venture investment arm with a donor-advised fund that awards research grants to early-stage scientists, leveraging both commercial returns and philanthropic capital deployment.
Summary
Reed Jobs, 34, leads Yosemite, a San Francisco-based venture capital fund managing over $1 billion in assets dedicated to oncology and life sciences innovation. The fund was established following Jobs' childhood experience watching his father, Apple co-founder Steve Jobs, battle pancreatic cancer—the disease that claimed his life in 2011 at age 56. This formative experience has driven Reed Jobs' explicit mission to reshape cancer treatment outcomes globally and position the disease as manageable rather than terminal.
Yosemite has established a notable portfolio across the healthcare startup ecosystem, with approximately 20 invested companies to date. Named investments include Tune Therapeutics, Azalea Therapeutics, Chai Discovery, and Sage Care, all US-based operations. The fund maintains strategic focus areas encompassing gene therapy, cancer vaccines, radiopharmaceuticals, and artificial intelligence applications in oncology. Beyond these publicly disclosed positions, Yosemite has also backed several UK-based companies whose names remain confidential.
The fund's institutional positioning reflects sophisticated capital structure design. Yosemite operates through a bifurcated model: a traditional for-profit venture investment vehicle alongside a donor-advised fund mechanism that distributes philanthropic grants to academic researchers conducting early-stage cancer science. This hybrid approach enables simultaneous commercial return generation and foundational research support. Key institutional partners include LifeArc, a UK-based nonprofit entity established in 2000 as a spinoff from the Medical Research Council, which itself invests in Yosemite. Additionally, Yosemite has established philanthropic grant partnerships with Oxford and Cambridge universities.
According to remarks made at a LifeArc-hosted life sciences conference in London, Reed Jobs emphasized active recruitment of additional UK investment opportunities, citing the quality of domestic research infrastructure. His stated rationale for UK market expansion centers on partnership development with pharmaceutical enterprises and academic institutions, reflecting confidence in the UK's oncology research capabilities and commercial prospects within the life sciences sector.
Yosemite has established a notable portfolio across the healthcare startup ecosystem, with approximately 20 invested companies to date. Named investments include Tune Therapeutics, Azalea Therapeutics, Chai Discovery, and Sage Care, all US-based operations. The fund maintains strategic focus areas encompassing gene therapy, cancer vaccines, radiopharmaceuticals, and artificial intelligence applications in oncology. Beyond these publicly disclosed positions, Yosemite has also backed several UK-based companies whose names remain confidential.
The fund's institutional positioning reflects sophisticated capital structure design. Yosemite operates through a bifurcated model: a traditional for-profit venture investment vehicle alongside a donor-advised fund mechanism that distributes philanthropic grants to academic researchers conducting early-stage cancer science. This hybrid approach enables simultaneous commercial return generation and foundational research support. Key institutional partners include LifeArc, a UK-based nonprofit entity established in 2000 as a spinoff from the Medical Research Council, which itself invests in Yosemite. Additionally, Yosemite has established philanthropic grant partnerships with Oxford and Cambridge universities.
According to remarks made at a LifeArc-hosted life sciences conference in London, Reed Jobs emphasized active recruitment of additional UK investment opportunities, citing the quality of domestic research infrastructure. His stated rationale for UK market expansion centers on partnership development with pharmaceutical enterprises and academic institutions, reflecting confidence in the UK's oncology research capabilities and commercial prospects within the life sciences sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.